Table 2. Overall Serious Infections in Patients With Psoriasis Receiving Systemic Medications Compared With Methotrexate for Optum Clinformatics Data Mart and Truven MarketScan .
| Exposure | Reference Group (MTX) | Exposure Group | Unadjusted Rate Difference (95% CI) | Unadjusted HR (95% CI) | P Value | PS-Adjusted HR (95% CI) | P Value | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients, No. | Events, No.a | Incidence Rateb | Patients, No. | Events, No. | Incidence Rate | ||||||
| Acitretin | |||||||||||
| Optum | 9048 | 127 | 14.46 | 2726 | 30 | 14.44 | −0.02 (−5.76 to 5.73) | 1.00 (0.67 to 1.50) | .99 | 1.33 (0.78 to 2.27) | .29 |
| MarketScan | 21 935 | 258 | 12.11 | 7456 | 81 | 13.68 | 1.57 (−1.75 to 4.90) | 1.14 (0.89 to 1.46) | .31 | 1.02 (0.76 to 1.38) | .87 |
| Adalimumab | |||||||||||
| Optum | 8470 | 112 | 14.24 | 7181 | 79 | 10.33 | −3.91 (−7.39 to −0.42) | 0.73 (0.55 to 0.98) | .03 | 1.26 (0.86 to 1.85) | .23 |
| MarketScan | 20 609 | 229 | 12.14 | 17 912 | 197 | 9.75 | −2.39 (−4.47 to −0.31) | 0.80 (0.66 to 0.97) | .02 | 1.02 (0.82 to 1.28) | .84 |
| Apremilast | |||||||||||
| Optum | 9383 | 134 | 14.62 | 1623 | 4 | 4.36 | −10.27 (−15.20 to −5.33) | 0.30 (0.11 to 0.80) | .02 | 0.39 (0.13 to 1.20) | .10 |
| MarketScan | 22 987 | 288 | 12.72 | 4476 | 11 | 5.35 | −7.37 (−10.86 to −3.88) | 0.45 (0.25 to 0.82) | .008 | 0.54 (0.27 to 1.09) | .09 |
| Etanercept | |||||||||||
| Optum | 8475 | 118 | 14.98 | 7102 | 68 | 8.05 | −6.94 (−10.25 to −3.63) | 0.54 (0.40 to 0.72) | <.001 | 0.78 (0.54 to 1.15) | .21 |
| MarketScan | 20 878 | 224 | 11.6 | 16 791 | 168 | 7.66 | −3.95 (−5.86 to −2.03) | 0.66 (0.54 to 0.80) | <.001 | 0.74 (0.59 to 0.93) | .01 |
| Infliximab | |||||||||||
| Optum | 9378 | 132 | 14.58 | 408 | 6 | 17.67 | 3.09 (−11.27 to 17.45) | 1.22 (0.54 to 2.76) | .62 | 2.01 (0.50 to 8.02) | .32 |
| MarketScan | 22 642 | 253 | 11.68 | 1027 | 20 | 17.08 | 5.41 (−2.22 to 13.03) | 1.44 (0.91 to 2.27) | .12 | 1.36 (0.67 to 2.73) | .39 |
| Ustekinumab | |||||||||||
| Optum | 9167 | 133 | 14.95 | 4085 | 21 | 5.57 | −9.37 (−12.86 to −5.89) | 0.38 (0.24 to 0.61) | <.001 | 0.54 (0.32 to 0.92) | .02 |
| MarketScan | 22 556 | 280 | 12.7 | 7841 | 56 | 7.06 | −5.63 (−8.01 to −3.26) | 0.56 (0.42 to 0.75) | <.001 | 0.70 (0.49 to 0.99) | .05 |
Abbreviations: HR, hazard ratio; MTX, methotrexate; PS, propensity score.
a
The sum of events in the subanalyses of serious infections may be greater than the number of events in the overall serious infection analysis if a patient experienced more than 1 serious infectious event.
b
Incident rate in 1000 person-years.